Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Clopidogrel on Myocardial Blood Flow in PAD
NCT02121288Phase 4Withdrawn
- Sponsor
- AstraZeneca
- Start
- Dec 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of ticagrelor in peripheral artery disease (PAD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Adenosine-induced Myocardial Blood Flow at Day 1. Planned start Dec 2014; status: withdrawn.
02
Drugs
ticagrelor
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT02121288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02121288.